Trabectedin in advanced desmoplastic round cell tumors: a retrospective single-center series

Area of Science:

• Oncology
• Medical Malignancies

Background:

• Desmoplastic Small Round Cell Tumor (DSRCT) is a rare, aggressive cancer.
• It presents with unpredictable chemosensitivity and limited treatment options.
• Prognosis for advanced DSRCT is generally poor.

Purpose of the Study:

• To evaluate the clinical activity of trabectedin in patients with advanced, unresectable DSRCT.
• To report on treatment response, progression, and adverse events associated with trabectedin therapy.

Main Methods:

• A case series of six patients with unresectable DSRCT treated with trabectedin.
• Assessment of disease progression, time to progression, and overall survival.
• Monitoring and reporting of grade 3-4 adverse events.

Main Results:

• Two patients achieved stable disease with limited time to progression (3 and 3.5 months).
• Four patients experienced disease progression after one cycle; some received subsequent treatments.
• Four patients had grade 3-4 adverse events, including thrombocytopenia and neutropenic fever.
• Median overall survival was poor at 4 months.

Conclusions:

• Trabectedin demonstrated limited clinical activity and efficacy in advanced DSRCT.
• Further research is necessary to identify more effective treatment strategies for this rare malignancy.